This is a U.S. news story, published by KFF Health News, that relates primarily to Donald Trump news.
For more U.S. news, you can click here:
more U.S. newsFor more Donald Trump news, you can click here:
more Donald Trump newsFor more health policy news, you can click here:
more health policy newsFor more news from KFF Health News, you can click here:
more news from KFF Health NewsOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like this article about health policy, you might also like this article about
Medicare price negotiations. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest high drug costs news, Medicare price negotiation news, news about health policy, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
lower drug pricesKFF Health News
•
80% Informative
Former President Donald Trump and Vice President Kamala Harris have a rare point of agreement: It’s up to the government to cut high U.S. drug prices.
As president, Trump would likely retain Medicare price negotiations unless the pharmaceutical industry can come up with something more compelling that they’d put on the table.
The drug industry could benefit, though, if Trump remains unable to advance such proposals.
Trump hasn’t said much about drug prices in his 2024 campaign, but allies and former advisers say he remains committed to knocking down prescription prices if reelected.
He would likely focus on increasing generic and biosimilar competition, importing drugs made in the U.S. but sold overseas.
Other goals may be lowering prices for drugs in the Medicare 340B program, which requires drugmakers to provide reduced prices to eligible health organizations.
VR Score
83
Informative language
84
Neutral language
51
Article tone
semi-formal
Language
English
Language complexity
63
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
8
Source diversity
7
Affiliate links
no affiliate links